Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9266226 | Immunology Letters | 2005 | 5 Pages |
Abstract
Interleukin-17 (IL-17) is a CD4 T cell-derived proinflammatry and proangiogenic cytokine. In this study, we investigated the effects of this cytokine on vascular endothelial cell growth induced by a well-known direct angiogenic factor bFGF, HGF, VEGF, CXCL5/ENA-78 or CXCL8/IL-8. While a wide range of doses of IL-17 alone did not show the ability to stimulate the growth of human dermal microvascular endothelial cells (HMVECs), bFGF, HGF, VEGF, CXCL5 or CXCL8 significantly induced the growth of HMVECs in vitro. When bFGF and IL-17 were used in combination, 10 or 100Â ng/ml IL-17 enhanced 10Â ng/ml bFGF-induced growth of HMVECs. Similarly, when HGF and IL-17 were combined together, 10 or 100Â ng/ml IL-17 potentiated 10Â ng/ml HGF-induced growth of HMVECs. When VEGF and IL-17 were used together, 10Â ng/ml IL-17 did not significantly enhance 10Â ng/ml VEGF-induced growth, whereas 100Â ng/ml IL-17 clearly promoted 10Â ng/ml VEGF-mediated proliferation of HMVECs. On the contrary, IL-17 did not augment CXCL5- and CXCL8-mediated growth. These results indicate that IL-17 itself does not have the capability to stimulate the growth of vascular endothelial cells, whereas IL-17 is able to selectively enhance the mitogenic activity of bFGF, HGF, and VEGF for vascular endothelial cells. Our findings also suggest that IL-17 may promote bFGF-, HGF- and VEGF-meadiated angiogenesis through enhancing bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Hidenori Takahashi, Muneo Numasaki, Michael T. Lotze, Hidetada Sasaki,